Prostate Cancer Discussions on CureTalks: Imaging Techniques, Genomic Tests, Focal Laser Ablation and Cancer Management -2016 Round Up
The Prostate Cancer segment on CureTalks saw the panel discussing new imaging techniques and genomic tests, focal laser ablation and prostate cancer management in 2016.
If you missed any of the talks, not to worry. The talks are available for playback along with their transcripts on CureTalks website.
How Will New Imaging Techniques and Genomic Tests Help In Diagnosis and Management of Prostate Cancer.
CureTalks featured Dr. David Lee, of University of Pennsylvania, in February 2016. Dr. Lee spoke at length about risk factors involved while using new imaging and genomic tests, how they may influence treatment. He also discussed Prolaris Test, multiparametric MRI, Oncotype DX in detail.
These new imaging and genomic tests have helped us to fine tune our treatment decisions. They also help us decide in some cases whether to do a biopsy and, maybe determine which patients are appropriate for active surveillance or more aggressive treatments.
Focal Laser Ablation in Treatment of Localized Prostate Cancer – A Developing Therapeutic Option
In November, Dr. Ara Karamanian of Prostate Laser Center, discussed the new developing treatment option of MRI guided focal laser ablation for localized prostate cancer. He came up against quite a few tough questions from the panel on the feasibility of the treatment option, patient eligibility, doctor expertise in the wake of non availability of statistically significant studies, results or publications. Dr. Karamanian answered all questions with patience and precision and shared lot of valuable information.
What is Value for Patients in the Management of Prostate Cancer.
Around the middle of the year 2016, CureTalks had a discussion on prostate cancer management with a panel of very active and experienced prostate cancer advocates. The topic handled extremely well by co-host Mike Scott, explored what is ‘value’ for a patient with prostate cancer . And below are some of the interesting insights:
A lot of people in the healthcare industry are trying to measure different aspects of value, and my bias is that they are doing this without a great deal of patient input.
I would think the greatest value was being told of other men like me in my circumstances who had continued to survive for years and decades and being put in touch with them and being given example from their lives of how cancer is not a death sentence, even aggressive prostate cancer.
The best value that I received were from sitting down and learning from other men how important it is to be responsible for my own healthcare and that means going and educating myself and learning about my options and making decisions based on myself and my ability to absorb the information
Its directly from my doctor in the same meeting with which he tells me that I have a little cancer down there. He pulled out a pen and paper, and he wrote down the phone numbers of three or four other options available. He told me what he would do to treat my disease and he gave me the phone number to actually surprising me myself and having been in the same business unit, but doctors in southern California and other locations that did different types of treatment, but he volunteered this information to me while I was still kind of getting over the word, “you have cancer.”
I think that I was very fortunate to have…, to be assigned a very good urologist who told me even though I had high Gleason score, that I had three or four months to make a decision as to what my treatment was, which gave me enough time to…, to think about the right way to go.
The discussion is a rewarding one. Don’t miss this one!
We will continue to feature interesting discussions on prostate cancer in the new year. If you have a topic you would like to hear discussed on CureTalks, please post it as a comment here or use our ‘Request a talk‘ option to let us know.